Every 8-K that Galecto, Inc. (GLTO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GLTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GLTO filings page.
Damora Therapeutics, Inc. announced a finance leadership change. The Board determined that, effective May 1, 2026, Lori Firmani will cease serving as Chief Financial Officer, principal financial officer, and principal accounting officer. Her departure benefits will follow the company’s Executive Separation Benefits Plan, with base salary continuation and pro-rated target bonus paid in a single lump sum, a $6,000 health savings account contribution, and full acceleration of all outstanding equity awards, subject to her signing a separation agreement and release.
The Board appointed Brian Burkavage, currently Senior Vice President, Finance, to serve as principal financial officer and principal accounting officer effective at the same time. Burkavage, age 43, has held senior finance roles at IO Biotech, Passage Bio, and Aclaris Therapeutics and previously spent 11 years at Ernst & Young. He will enter into Damora’s standard executive indemnification agreement, and the company states he has no disclosable related-party transactions or family relationships with directors or executives.
Damora Therapeutics, Inc. changed its independent auditor. On April 17, 2026, the Audit Committee dismissed EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm and appointed Ernst & Young LLP (EY US) effective immediately.
EY Denmark’s reports on the Company’s financial statements for 2025 and 2024 contained no adverse or qualified opinions, although the 2024 report included an explanatory paragraph about the Company’s ability to continue as a going concern. The Company reports no disagreements or reportable events with EY Denmark and states that it did not consult EY US on accounting or auditing matters before the engagement.
Damora Therapeutics announced a major leadership and board refresh. The Board appointed Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026, and she will also join the Board. Her offer includes a $695,000 base salary, a target bonus equal to 55% of salary, 500,000 restricted stock units vesting over four years, and options to purchase 1,500,000 shares vesting over four years, with enhanced severance and accelerated vesting protections around a change in control.
Current COO Sherwin Sattarzadeh will step down as principal executive officer but remain Chief Operating Officer. Directors Amit Munshi, Carl Goldfischer and Jayson Dallas resigned, with their equity awards fully accelerated, and the Board size was reduced from seven to six. Michael Landsittel and Cameron Turtle were appointed as Class III directors and will receive options under the 2026 Equity Incentive Plan, while Peter Harwin was named Board chair. Damora also updated compensation and severance terms for General Counsel Garrett Winslow, including a $440,000 salary, a 40% target bonus and options for 250,000 shares.
Damora Therapeutics, Inc., formerly Galecto, Inc., has changed its corporate name and will begin trading on Nasdaq under the new symbol “DMRA” starting March 10, 2026. The name change does not affect shareholder voting rights or the validity of existing common stock.
The company reported preliminary, unaudited cash and cash equivalents of approximately $535 million as of February 28, 2026, supporting plans to advance its mutant calreticulin–targeted pipeline. Damora expects to submit regulatory applications for lead antibody DMR-001 in mid‑2026 and aims for two clinical proof‑of‑concept datasets beginning mid‑2027, with cash runway anticipated into Phase 3 development of DMR-001.
Galecto, Inc. entered into an underwriting agreement to sell 14,473,685 shares of common stock at $19.00 per share, with underwriters granted a 30‑day option to buy up to an additional 2,171,052 shares on the same terms, which was exercised in full. Net proceeds to the company from this offering are approximately $295.9 million after underwriting discounts and estimated expenses. Galecto expects these funds, together with existing cash and cash equivalents, to be sufficient to finance operations into Phase 3 development of its candidate DMR-001, although it notes this estimate depends on assumptions that may prove incorrect. The shares are being issued under an automatic shelf registration statement on Form S-3, with the offering expected to close on February 12, 2026.
Galecto, Inc. announced major corporate changes centered on leadership and capital structure. The board determined that, effective February 10, 2026, Hans T. Schambye will step down as Chief Executive Officer and President and resign from the board, with no disagreement cited over operations or policies. Subject to a separation agreement, he will receive benefits under his retention agreement and the Executive Separation Benefits Plan, including lump-sum severance and full acceleration of all outstanding equity awards.
The board appointed current Chief Operating Officer Sherwin Sattarzadeh as interim principal executive officer, with his existing offer letter continuing to govern his employment. At a February 9, 2026 special meeting, stockholders approved the issuance of common shares upon conversion of Series B and Series C preferred stock, an increase in authorized common shares from 300,000,000 to 500,000,000, a redomestication from Delaware to the Cayman Islands, and new 2026 equity incentive and employee stock purchase plans. Following automatic conversion of 42,005 shares of Series C preferred into 42,005,000 common shares, the company had approximately 43.6 million common shares outstanding as of February 9, 2026.
Galecto, Inc. reported that it plans to meet with securities analysts, investors and others in connection with the 44th Annual J.P. Morgan Healthcare Conference beginning on January 12, 2026. During these meetings, the company expects to use a corporate slide presentation that is included as Exhibit 99.1, titled “Corporate Presentation (January 2026). The information related to these meetings and the presentation is being furnished under Regulation FD, meaning it is not treated as filed for purposes of the Securities Exchange Act of 1934 and is not subject to the associated liability provisions or automatically incorporated into other securities law filings.
Galecto, Inc. reported two key developments. The company issued a warrant to Paramora Holding LLC on December 31, 2025 to purchase up to 628,302 shares of common stock at an exercise price of $23.01 per share, relying on a private offering exemption under Section 4(a)(2) of the Securities Act. The warrant is effective as of that date and expires 10 years later.
Galecto also appointed Sherwin Sattarzadeh as Chief Operating Officer, effective January 5, 2026. His offer letter provides a base salary of $540,000, a target annual bonus equal to 40% of base salary, severance protections that increase in connection with a sale event, and company-subsidized health coverage for up to 18 months in certain termination scenarios. As an inducement grant, he will receive 190,376 restricted stock units vesting over four years and options to purchase 444,209 shares vesting over four years.
Galecto (GLTO) completed the acquisition of Damora Therapeutics and lined up new capital. The company issued 265,309 shares of common stock, 16,366 shares of Series B Non-Voting Convertible Preferred Stock, and 4,241 shares of Series C Non-Voting Convertible Preferred Stock to Damora holders. Each preferred share is convertible into 1,000 common shares, subject to stockholder approval of a conversion proposal and related items.
Galecto also entered a private placement to sell 39,641 Series C preferred shares for approximately $285 million, with closing expected on November 12, 2025. A registration rights agreement requires filing a resale registration statement within 45 days of closing. Certain holders agreed to a 180‑day lockup. Board changes included three director resignations and the appointments of Peter Harwin, Chris Cain, Ph.D., and Julianne Bruno. The company plans to seek stockholder approval for the conversion proposal, a redomicile, and a potential charter amendment that may include a reverse stock split to maintain Nasdaq compliance.